MMMakoto Masaki

Makoto Masaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Makoto Masaki has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Arata Oka

    Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan

    1 shared publication
  • Hajime Yamazaki

    Department of Community Medicine Section of Clinical Epidemiology Graduate School of Medicine Kyoto University Kyoto Japan

    1 shared publication
  • Haruka Toyonaga

    Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan

    1 shared publication
  • Hidetoshi Nakata

    Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan

    1 shared publication
  • Hironao Matsumoto

    Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan

    1 shared publication
  • Kimi Sumimoto

    Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and Safety of Remimazolam Compared to Midazolam for Sedation During Endoscopic Ultrasonography: A Single‐Center Retrospective Cohort Study

    by Haruka Toyonaga, Makoto Masaki, Hajime Yamazaki, Arata Oka, Yoshiki Matsuno, Hidetoshi Nakata, Shoji Takayama, Tatsuya Nakagawa, Takuya Takayama, Masahiro Orino, et al.

    Objectives: Remimazolam is a novel ultra–short‐acting benzodiazepine that may offer advantages over conventional sedatives in endoscopic procedures. Evidence for its use in pancreatobiliary endoscopic ultrasonography (EUS) is limited. We compared the efficacy and safety of remimazolam and midazolam in outpatient pancreatobiliary EUS. Methods: This retrospective study included outpatients undergoing diagnostic pancreatobiliary EUS between July 2024 and July 2025. Patients received either remimazolam (initial 0.2 mg/kg, top‐up 0.1 mg/kg [high‐risk patients: 0.16 mg/kg, 0.08 mg/kg]) or midazolam. The target sedation depth was Modified Observer's Assessment of Alertness/Sedation ≤3, procedures were performed without supplemental oxygen, and pentazocine was co‐administered. The primary outcome was rapid recovery (meeting all criteria: modified Aldrete score ≥6 at 5 min, ≥9 at 30 min, ambulation ≥3 m at 30 min). Secondary outcomes included sedation success (all: EUS completion, without >2 top‐ups within 10 min, without rescue sedation, without agitation requiring interruption), recovery time, flumazenil use, and adverse events. Results: We analyzed 139 patients (remimazolam, n = 75; midazolam, n = 64). Rapid recovery was more frequent with remimazolam (70.7% vs. 25.0%, p < 0.001). Sedation success was higher (92.0% vs. 73.4%, p = 0.005), recovery was shorter (median 34 vs. 55 min, p < 0.001), and flumazenil use was lower (4.0% vs. 45.3%, p < 0.001). Hypoxemia (SpO 2 p = 0.707), but all episodes were mild and reversible with airway support/oxygen. Hypotension was rare and comparable. Conclusions: Remimazolam provided faster recovery and higher sedation success than midazolam in outpatient pancreatobiliary EUS. Supplemental oxygen before sedation is a reasonable option to enhance safety.